Ultraviolet Rays Clinical Trial
Official title:
The First in the World Human Proof-of-concept Study on Disinfection and Healing Acceleration Capabilities of 222nm Wave Length Narrow Band Ultraviolet Lighting Device
The threat of MRSA and multi-drug resistant pathogens have been growing in recent years. A new means of countering the infectious threat is required and one such modality is the use of UV light for disinfection. The aim of the study is to proof the efficacy of the 222nm UV light in disinfection on patients with sacral sores. This is a first in human proof-of-concept study
Recent outbreaks of Ebola and MERS, and in the trend of growing threat of MRSA and multi-drug
resistant pathogens, it is clear that a new means of countering the infectious threat is
needed - even the US, EU, and Korean hospitals with the latest facilities has failed to stop
the spread of these pathogens inside their wards.
This novel "Harmless UV Light," operating within the "Safe Zone Wave Length," will be a
disruptive technology to counter the growing threats of infectious diseases, such as
multi-drug-resistant bacteria and also viruses such as Ebola, MERS and new type Influenza. It
will be a disruptive device in that it aims to be applied to fast, effective and labor-free
disinfection of living environments, such as hospital wards, airports, and other public
spaces to stop the spread of pathogens. This research is the first human clinical trial using
this device that will spearhead the development of this technology, providing the key
starting clinical data which would be the lead to development for a wider range of
indications and markets. Successful proof of concept will lead to the next stage
collaboration of larger scale clinical trials, and trials targeting wider range of
indications and markets, at NUHS.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00705887 -
A Motivational Enhancement Approach to Skin Cancer Prevention
|
N/A | |
| Completed |
NCT01978483 -
Effect of RANKL Inhibition on UV-induced Immunosuppression
|
Phase 1 | |
| Completed |
NCT00685438 -
Ultraviolet Exposure, Antioxidant Use and Skin Erythema at Extreme High Altitude
|
N/A |